UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000038045
Receipt No. R000043367
Scientific Title Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers
Date of disclosure of the study information 2020/12/19
Last modified on 2019/12/26 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers
Acronym Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers
Scientific Title Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers
Scientific Title:Acronym Effects of lactic acid bacteria intake on perimenopausal women on menopause-like symptoms, sleep and biomarkers
Region
Japan

Condition
Condition Healthy adult
Classification by specialty
Adult
Classification by malignancy Others
Genomic information YES

Objectives
Narrative objectives1 To investigate the effects of lactic acid bacteria on menopause-like symptoms, sleep and biomarkers after 8 weeks of ingestion.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes Kupperman Kohnenki Shogai Index (KKSI) at 8 weeks ingestion
Key secondary outcomes 1. Swelling
2. Blood flow
3. Stiff shoulder VAS
4. QOL questionnaire (SF-36)
5. Pittsburgh Sleep Quality Index (PSQI-j)
6. OSA sleep inventory MA version
7. Heart rate / activity survey

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Ingestion of test food anytime except before going to bed. Or ingestion of test food before going to bed.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
45 years-old <=
Age-upper limit
55 years-old >
Gender Female
Key inclusion criteria (1) Female older than 45 years and younger than 55 years
(2) Subjects who are aware of aging irregular menstruation, indefinite complaints and poor sleep
(3) Subjects who can appropriately conduct heart rate and activity surveys
(4) Subjects judged to be healthy by a doctor
Key exclusion criteria (1) Subjects who can not properly collect hair, saliva and blood flow test
(2) Subjects with history, treatment history, medication, or health food intake affecting the assessment of climacteric symptoms
(3) Subjects with history, treatment history, medication, or health food consumption that affect sleep assessment
(4) Subjects who have passed more than one year after menopause
(5) Subjects who take excessive amounts of soybean products such as natto and soy beverages
(6) Subjects who take foods rich in lactic acid bacteria (yogurt, lactic acid bacteria beverages, etc.) at least three times a week
(7) Subjects who have undergone oophorectomy or hysterectomy
(8) Excessive smokers, alcohol addicts, and subjects with extremely irregular diets
(9) Subjects whose overall score of the Pittsburgh Sleep Questionnaire at the pre-examination is less than 3, or more than 10, or who are estimated to have sleep disorders such as insomnia from the answers
(10) Subjects whose BMI are 30.0 kg/m^2 or more
(11) Subjects who are awakened midway through external factors such as child crying at least twice a week
(12) Night and day shift worker or manual laborer
(13) Subjects who have under treatment or a history of serious disease (e.g., diabetes, liver disease, kidney disease, or heart disease) and disease to affect the adrenal cortical hormone secretion
(14) Subjects who are judged as unsuitable for the study based on the results of lifestyle questionnaire
(15) Subjects who are judged as unsuitable for the study because of clinical test, anthropometric test and physical examination in pre-inspection
(16) Subjects who have participated in other clinical study within the last one month or have plan to participate other clinical studies
(17) Subjects who are pregnant or lactating, or plan to become pregnant or lactate during the study
(18) Subjects who are judged as unsuitable for the study by investigator for other reasons
Target sample size 10

Research contact person
Name of lead principal investigator
1st name Soichi
Middle name
Last name Tanabe
Organization NISSIN FOODS HOLDINGS CO., LTD.
R&D Platform NISSIN Global Innovation Center
Division name Health Science Research Office
Zip code 192-0001
Address 2100, Tobukimachi, Hachioji, Tokyo
TEL 042-696-7685
Email soichi.tanabe@nissin.com

Public contact
Name of contact person
1st name Shinsuke
Middle name
Last name Tsuji
Organization TTC Co., Ltd.
Division name Clinical Research Planning Department
Zip code 150-0021
Address Seibu Shinkin Bank Ebisu Bldg.,1-20-2, Ebisunishi, Shibuya-ku, Tokyo
TEL 03-5459-5329
Homepage URL
Email s.tsuji@ttc-tokyo.co.jp

Sponsor
Institute TTC Co., Ltd.
Institute
Department

Funding Source
Organization NISSIN FOODS HOLDINGS CO., LTD.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Aisei Hospital Ueno Clinic Research Ethics Committee
Address 2-18-6, Higashiueno, Taitou-ku, Tokyo
Tel 03-6455-0880
Email t.saito@ttc-smo.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 12 Month 19 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2019 Year 09 Month 12 Day
Date of IRB
2019 Year 09 Month 12 Day
Anticipated trial start date
2019 Year 09 Month 20 Day
Last follow-up date
2019 Year 12 Month 20 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2019 Year 09 Month 18 Day
Last modified on
2019 Year 12 Month 26 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043367